Parexel International Corp. (NASDAQ:PRXL) was downgraded by analysts at SunTrust Banks Inc. from a “buy” rating to a “hold” rating in a report issued on Friday. They currently have a $60.00 target price on the stock, down from their previous target price of $80.00. SunTrust Banks Inc.’s price objective suggests a potential upside of 6.10% from the stock’s previous close.

A number of other research firms have also weighed in on PRXL. Credit Suisse Group AG restated a “buy” rating on shares of Parexel International Corp. in a research report on Tuesday, September 27th. Deutsche Bank AG boosted their target price on shares of Parexel International Corp. from $65.00 to $71.00 and gave the company a “hold” rating in a report on Friday, August 5th. Citigroup Inc. boosted their target price on shares of Parexel International Corp. from $74.00 to $80.00 and gave the company a “buy” rating in a report on Friday, August 5th. Evercore ISI reiterated a “buy” rating and issued a $78.50 target price (up from $71.00) on shares of Parexel International Corp. in a report on Friday, August 5th. Finally, Jefferies Group boosted their target price on shares of Parexel International Corp. from $70.00 to $72.50 and gave the company a “hold” rating in a report on Friday, August 5th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $67.56.

Analyst Recommendations for Parexel International Corp. (NASDAQ:PRXL)

Parexel International Corp. (NASDAQ:PRXL) opened at 56.55 on Friday. The stock’s 50 day moving average is $64.39 and its 200-day moving average is $64.31. The company has a market capitalization of $3.01 billion, a P/E ratio of 17.83 and a beta of 0.91. Parexel International Corp. has a 1-year low of $51.16 and a 1-year high of $71.13.

Parexel International Corp. (NASDAQ:PRXL) last posted its quarterly earnings results on Wednesday, October 26th. The company reported $0.76 earnings per share for the quarter, missing analysts’ consensus estimates of $0.86 by $0.10. The business had revenue of $500.90 million for the quarter, compared to analyst estimates of $525.15 million. Parexel International Corp. had a return on equity of 30.68% and a net margin of 7.09%. The business’s revenue was down 2.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.70 earnings per share. On average, analysts expect that Parexel International Corp. will post $3.76 earnings per share for the current fiscal year.

A number of large investors have recently made changes to their positions in PRXL. Endurant Capital Management LP acquired a new stake in shares of Parexel International Corp. during the third quarter valued at $701,000. Gotham Asset Management LLC acquired a new stake in shares of Parexel International Corp. during the third quarter valued at $4,496,000. Clinton Group Inc. increased its stake in shares of Parexel International Corp. by 775.2% in the third quarter. Clinton Group Inc. now owns 38,003 shares of the company’s stock valued at $2,639,000 after buying an additional 33,661 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of Parexel International Corp. during the third quarter valued at $30,564,000. Finally, UBS Group AG increased its stake in shares of Parexel International Corp. by 2.0% in the third quarter. UBS Group AG now owns 3,131,814 shares of the company’s stock valued at $217,504,000 after buying an additional 61,474 shares during the last quarter. 95.54% of the stock is currently owned by hedge funds and other institutional investors.

Parexel International Corp. Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company, which provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology and medical device industries across the world.

5 Day Chart for NASDAQ:PRXL

Receive News & Stock Ratings for Parexel International Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parexel International Corp. and related stocks with our FREE daily email newsletter.